Gene · 2921
NIH grants2,607
NIH grants whose papers are about the gene, through NIH's grant-paper links.
881 to 900 of 2,607
Download this page as JSON| Grant | Title | CXCL3 papers | Newest fiscal year |
|---|---|---|---|
| R01CA096500 | Role of KSHV Viral Proteins in Signaling and Pathogenesis | 1 | 2022 |
| R01CA155169 | Understanding Resistance to Next Generation Antiandrogens | 1 | 2022 |
| R01CA164605 | Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma | 1 | 2022 |
| R01CA196232 | Effectors of protein kinase C-mediated tumor progression | 1 | 2022 |
| R01CA204021 | Target MIC shedding to revive anti-tumor immunity | 1 | 2022 |
| R01CA211014 | CD200R signaling in tumor growth, immunity and immunotherapy | 1 | 2022 |
| R01CA215481 | Translation addiction and targeting in colon cancer | 1 | 2022 |
| R01CA216855 | A novel microfluidic device to predict brain cancer prognosis and response to therapy | 1 | 2022 |
| R01CA218133 | Mechanisms of cytokine driven tumor elicited inflammation in colorectal cancer | 1 | 2022 |
| R01CA218579 | Single Cell Genome-Wide Myeloid Response Profiling in Immunotherapy | 1 | 2022 |
| R01CA219670 | Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors. | 1 | 2022 |
| R01CA220237 | UBAP2, A New Molecule in Pancreatic Cancer Progression | 1 | 2022 |
| R01CA221158 | Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer | 1 | 2022 |
| R01CA224493 | Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs | 1 | 2022 |
| R01CA224769 | Integrin-mediated mechanisms of prostate cancer progression | 1 | 2022 |
| R01CA227629 | The role of Interleukin 17RB signaling in colorectal cancer progression | 1 | 2022 |
| R01CA229803 | Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer | 1 | 2022 |
| R01CA239342 | Statistical methods and tools for cancer risk prediction in families with germline mutations in TP53 | 1 | 2022 |
| R01CA241816 | Identification of REV-ERB inverse agonists for cancer immunotherapy | 1 | 2022 |
| R01DA046171 | Identification and Regulation of RNA Modification by HIV infection and Methamphetamine | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2921/grants?page=45